Copyright
©The Author(s) 2016.
Figure 8 Percent sera of MS patients treated with Betaferon, Avoex and Rebif, containing anti-IFNβ, anti-advanced glycation endproducts Abs, and responding to Advanced glycation endproducts-bovine serum albumin inhibition of binding to IFNβ.
For detailed information on the experimental conditions see ref. No. 211. AGEs-BSA: Advanced glycation endproducts-bovine serum albumin.
- Citation: Tsekovska R, Sredovska-Bozhinov A, Niwa T, Ivanov I, Mironova R. Maillard reaction and immunogenicity of protein therapeutics. World J Immunol 2016; 6(1): 19-38
- URL: https://www.wjgnet.com/2219-2824/full/v6/i1/19.htm
- DOI: https://dx.doi.org/10.5411/wji.v6.i1.19